Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock Based Compensation (Tables)

Stock Based Compensation (Tables)

6 Months Ended

Jun. 30, 2012

Weighted-Average fair value valuation assumptions


	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Employee Stock Options
Risk-free interest rate		1.13	%		1.93	%		1.14	%		1.93	%
Expected term (in years)		5.96			5.96			5.98			5.97
Dividend yield		—			—			—			—
Volatility		107	%		91	%		107	%		91	%
Weighted-average fair value of stock options granted	$	5.64		$	1.23		$	5.03		$	1.23


	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Employee Stock Purchase Plan (ESPP):
Risk-free interest rate		0.20	%		0.5	%		0.20	%		0.5	%
Expected term (in years)		1.25			1.25			1.25			1.25
Dividend yield		—			—			—			—
Volatility		111	%		79	%		111	%		79	%
Weighted-average fair value of ESPP purchase rights	$	2.04		$	0.84		$	2.04		$	0.84

Stock-Based compensation expense


	Three Months Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
Amortization of stock-based compensation:
Research and development	$	370	$	88	$	611	$	188
General and administrative		374		114		532		264

	$	744	$	202	$	1,143	$	452

Stock option activity under equity incentive plan


Options	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2011		3,672,179		$	1.45		—		—
Granted		1,591,000		$	6.13		—		—
Exercised		(191,301	)	$	1.27		—		—
Forfeitures		—		$	—		—		—

Outstanding at June 30, 2012		5,071,878		$	2.92		8.40	$	22,700,291

Vested and expected to vest June 30, 2012		5,005,471		$	2.90		8.39	$	22,514,740
Exercisable at June 30, 2012		1,964,595		$	1.55		7.32	$	11,492,141

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details